跳转至内容
Merck
CN

SML2733

RLA8

≥98% (HPLC)

别名:

8-[3-Methoxy-5-[(1E)-2-(4-methoxyphenyl)ethenyl]phenoxy]octanoic acid

登录 查看组织和合同定价。

选择规格

变更视图

关于此项目

经验公式(希尔记法):
C24H30O5
化学文摘社编号:
分子量:
398.49
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
powder
Storage condition:
protect from light
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


Quality Segment

assay

≥98% (HPLC)

form

powder

storage condition

protect from light

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

O(CCCCCCCC(=O)O)c1cc(cc(c1)\C=C\c2ccc(cc2)OC)OC

InChI

1S/C24H30O5/c1-27-21-13-11-19(12-14-21)9-10-20-16-22(28-2)18-23(17-20)29-15-7-5-3-4-6-8-24(25)26/h9-14,16-18H,3-8,15H2,1-2H3,(H,25,26)/b10-9+

InChI key

MNKZDYGBWDHRMX-MDZDMXLPSA-N

Biochem/physiol Actions

RLA8 is an orally available and potent agonist of peroxisome proliferator-activated receptors (PPARs)-α/γ/δ and G-protein-coupled receptor 40 (GPR40). RLA8 reverses the proregression of pathological changes such as hepatic lipid accumulation, steatosis, inflammation and fibrosis in mice models of nonalcoholic steatohepatitis (NASH). Also, it improves serum HDL cholesterol, reduce hepatic free fatty acid and triglyceride levels, and alleviate insulin resistance.
orally available and potent agonist for PPARs-α/γ/δ and GPR40 that exhibits efficacy to reverse nonalcoholic steatohepatitis and fibrosis


存储类别

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库